Publications by authors named "Chong-Bing Liu"
Pirfenidone promotes cell cycle arrest and apoptosis of triple‑negative breast cancer cells by suppressing Hedgehog/GLI1 signaling.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Article Synopsis
- Breast cancer, especially triple-negative breast cancer (TNBC), presents a significant challenge due to its aggressive nature and poor prognosis, prompting research into potential treatments like pirfenidone, an FDA-approved drug with anti-fibrotic and emerging anti-tumor properties.
- In experiments, pirfenidone was shown to reduce cell viability and proliferation in TNBC cell lines (MDA-MB-231 and HCC-1937), shifting more cells into the G0/G1 phase of the cell cycle and inducing apoptosis by altering specific protein expressions related to cell survival and apoptosis.
- The study revealed that pirfenidone's effectiveness is linked to its suppression of the Hedgehog/GLI1 signaling pathway, as